Skip to content

A randomized double-blind placebo-controlled multicenter clinical study of Jieyu Anshen Fang in the treatment of elderly depression with liver qi stagnation type

A randomized double-blind placebo-controlled multicenter clinical study of Jieyu Anshen Fang in the treatment of elderly depression with liver qi stagnation type

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000478
Enrollment
Unknown
Registered
2024-09-25
Start date
2024-10-08
Completion date
Unknown
Last updated
2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depression

Interventions

Experimental group:Jieyu Anshen Fang
control group:Jieyu Anshen Fang Simulator

Sponsors

Hubei Provincial Traditional Chinese Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Outpatient patients aged 60 years or older with clear consciousness normal comprehension and language expression abilities; 2. Meets the diagnostic criteria for major depressive disorder in the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5); 3. According to traditional Chinese medicine syndrome differentiation it is depression of liver qi stagnation type; 4. HAMD-17 scores in the screening/cleansing period and baseline period are between 18 points and a total score of 24 points and the first item (depressive mood) score is = 2 points; 5. The baseline HAMA total score is = 14 points and the first item (anxious mood) is<3 points and the sixth item (depressed mood) is = 2 points; 6. Understand the experimental steps and content and voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. The total score of HAMD-17 in the baseline period decreased by more than 25% compared to the screening/cleaning period; 2. Have a history of attempted suicide or currently have a high risk of suicide or have a HAMD-17 score of = 3 on the third criterion (suicide score); 3. Severe anxiety HAMA score>21; 4. Individuals who have taken fluoxetine within the past 5 weeks prior to screening; 5. Patients with severe or unstable physical diseases such as heart liver kidney endocrine digestive and hematological disorders; Patients with combined organic brain diseases or malignant tumors; 6. Abnormal liver function (ALT and AST exceeding the upper limit of normal values by 2 times) abnormal kidney function (BUN and Cr abnormalities); 7. Clinically significant electrocardiogram abnormalities; 8. Patients with refractory depression; Individuals with a history of epilepsy except for febrile seizures in childhood; 9. According to the DSM-5 diagnostic criteria individuals with alcohol and drug dependence within one year; 10. Individuals with depression secondary to other mental or physical illnesses; 11. The author of depression accompanied by psychotic symptoms; 12. Individuals with communication barriers or those who are unable to take medication according to medical advice; 13. Individuals allergic to research drug related ingredients; 14. Pregnant lactating or recently planned pregnancies; 15. The researchers believe that patients who are not suitable to participate in this clinical trial.

Design outcomes

Primary

MeasureTime frame
HAMD-17 rating;

Secondary

MeasureTime frame
HAMA rating;ISI rating;Traditional Chinese Medicine Syndrome Scoring;CGI score (disease severity);MADRS score;

Countries

China

Contacts

Public ContactChen Gang

Hubei Provincial Traditional Chinese Medicine Hospital

Sammi200x@163.com13986179621

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026